Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026)
Oculis Holding AG (OCS) posted quarterly Return on Capital Employed of 31.8% for Q1 2026, up 1648.0% year-over-year from 1.82% in Q1 2025, and up 10.2% quarter-over-quarter from 35.41% in Q4 2025.
Oculis Holding AG (OCS) Return on Capital Employed (2023 - 2026) Analysis & Trends
Oculis Holding AG's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 31.8% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1648.0% year-over-year to 31.8%; the TTM figure through Mar 2026 stood at 31.8% (up 1648.0% YoY), while the FY2025 annual figure was 59.21%, up 4254.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 31.8%, up from 35.41% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.8% in Q1 2026, with the low at 76.62% in Q4 2023.
- The 4-year median for Return on Capital Employed is 48.28% (2025), against an average of 52.66%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 808 bps in 2024, then surged 3312 bps in 2025.
- Oculis Holding AG's Return on Capital Employed stood at 76.62% in 2023, then grew by 11 bps to 68.53% in 2024, then jumped by 48 bps to 35.41% in 2025, then increased by 10 bps to 31.8% in 2026.
- Business Quant data shows OCS's Return on Capital Employed at 31.8% in Q1 2026, 35.41% in Q4 2025, and 38.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -32.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.53% |
| Mar 31, 2026 | -31.80% |
| Dec 31, 2025 | -35.41% |
| Sep 30, 2025 | -38.87% |
| Jun 30, 2025 | -37.43% |
| Mar 31, 2025 | -48.28% |
| Dec 31, 2024 | -68.53% |
| Sep 30, 2024 | -47.94% |
| Jun 30, 2024 | -66.13% |
| Mar 31, 2024 | -57.80% |
| Dec 31, 2023 | -76.62% |
| Sep 30, 2023 | -70.48% |